ACAD
Price
$14.62
Change
+$0.27 (+1.88%)
Updated
Apr 23 closing price
Capitalization
2.39B
19 days until earnings call
RGNX
Price
$8.87
Change
+$1.05 (+13.43%)
Updated
Apr 23 closing price
Capitalization
391.91M
6 days until earnings call
Ad is loading...

ACAD vs RGNX

Header iconACAD vs RGNX Comparison
Open Charts ACAD vs RGNXBanner chart's image
ACADIA Pharmaceuticals
Price$14.62
Change+$0.27 (+1.88%)
Volume$1.57M
Capitalization2.39B
REGENXBIO
Price$8.87
Change+$1.05 (+13.43%)
Volume$1.7M
Capitalization391.91M
ACAD vs RGNX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. RGNX commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and RGNX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ACAD: $14.62 vs. RGNX: $8.87)
Brand notoriety: ACAD and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 94% vs. RGNX: 165%
Market capitalization -- ACAD: $2.39B vs. RGNX: $391.91M
ACAD [@Biotechnology] is valued at $2.39B. RGNX’s [@Biotechnology] market capitalization is $391.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 6 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 6 bullish, 2 bearish.
  • RGNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than RGNX.

Price Growth

ACAD (@Biotechnology) experienced а +0.34% price change this week, while RGNX (@Biotechnology) price change was +43.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.39B) has a higher market cap than RGNX($392M). RGNX YTD gains are higher at: 14.748 vs. ACAD (-20.327). ACAD has higher annual earnings (EBITDA): 100M vs. RGNX (-198.23M). ACAD has more cash in the bank: 756M vs. RGNX (235M). ACAD has less debt than RGNX: ACAD (52M) vs RGNX (82M). ACAD has higher revenues than RGNX: ACAD (958M) vs RGNX (83.3M).
ACADRGNXACAD / RGNX
Capitalization2.39B392M610%
EBITDA100M-198.23M-50%
Gain YTD-20.32714.748-138%
P/E Ratio10.55N/A-
Revenue958M83.3M1,150%
Total Cash756M235M322%
Total Debt52M82M63%
FUNDAMENTALS RATINGS
ACAD vs RGNX: Fundamental Ratings
ACAD
RGNX
OUTLOOK RATING
1..100
1415
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2595
PRICE GROWTH RATING
1..100
7776
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (58) in the Biotechnology industry is in the same range as RGNX (76). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for RGNX (95). This means that ACAD’s stock grew significantly faster than RGNX’s over the last 12 months.

RGNX's Price Growth Rating (76) in the Biotechnology industry is in the same range as ACAD (77). This means that RGNX’s stock grew similarly to ACAD’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for ACAD (100). This means that RGNX’s stock grew significantly faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADRGNX
RSI
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 10 days ago
73%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CRMEX5.69N/A
N/A
CRM All Cap Value Inv
GCCSX28.29N/A
N/A
Gabelli Small Cap Growth C
MXVIX33.92N/A
N/A
Empower S&P 500® Index Investor
DHTYX21.45N/A
N/A
Diamond Hill Select Y
MPDRX8.46N/A
N/A
MassMutual Disciplined Gr R3

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.88%
RGNX - ACAD
48%
Loosely correlated
+13.43%
HRTX - ACAD
44%
Loosely correlated
+2.33%
XNCR - ACAD
42%
Loosely correlated
+2.07%
RCKT - ACAD
41%
Loosely correlated
+2.44%
COGT - ACAD
41%
Loosely correlated
+3.00%
More